Therefore, disruption of the pro-survival function of GCDA by blocking phosphorylation and nuclear accumulation of ERK1/2 molecules represents tactics for treating GCDA-related liver cancer and chemoresistance. The gene discussed is MAPK3; the disease is liver cancer.